BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic by Carolyn Helms | May 29, 2025 | Portfolio News
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease by Carolyn Helms | May 20, 2025 | Portfolio News
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) by Carolyn Helms | May 20, 2025 | Portfolio News
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma by Carolyn Helms | May 19, 2025 | Portfolio News
Cohere Health Secures $90M Series C to Expand AI-Powered Platform Transforming Health Plan Clinical Decision-Making by Carolyn Helms | May 14, 2025 | Portfolio News
Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025 by Carolyn Helms | May 3, 2025 | Portfolio News
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025 by Carolyn Helms | Apr 28, 2025 | Portfolio News
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting by Carolyn Helms | Apr 26, 2025 | Portfolio News
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 by Carolyn Helms | Apr 24, 2025 | Portfolio News
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer by Carolyn Helms | Apr 2, 2025 | Portfolio News
